Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Price Target Raised to $90.00

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) had its price objective increased by The Goldman Sachs Group from $75.00 to $90.00 in a report issued on Thursday morning,Benzinga reports. The brokerage currently has a buy rating on the stock.

A number of other equities research analysts have also recently weighed in on KNSA. JPMorgan Chase & Co. lifted their price target on shares of Kiniksa Pharmaceuticals International from $72.00 to $107.00 and gave the company an “overweight” rating in a research report on Wednesday. Canaccord Genuity Group upped their price objective on shares of Kiniksa Pharmaceuticals International from $64.00 to $98.00 and gave the stock a “buy” rating in a report on Wednesday. Zacks Research raised shares of Kiniksa Pharmaceuticals International from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, June 17th. Citigroup lifted their target price on shares of Kiniksa Pharmaceuticals International from $60.00 to $100.00 and gave the company a “buy” rating in a report on Wednesday. Finally, Weiss Ratings downgraded shares of Kiniksa Pharmaceuticals International from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday, June 23rd. Nine analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat.com, Kiniksa Pharmaceuticals International presently has an average rating of “Moderate Buy” and an average price target of $87.38.

Kiniksa Pharmaceuticals International Trading Down 4.9%

Shares of NASDAQ:KNSA opened at $74.34 on Thursday. The business has a 50-day moving average price of $59.04 and a 200 day moving average price of $51.13. The company has a market capitalization of $5.72 billion, a price-to-earnings ratio of 76.64 and a beta of 0.07. Kiniksa Pharmaceuticals International has a 12-month low of $29.90 and a 12-month high of $82.94.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last issued its quarterly earnings data on Tuesday, July 28th. The company reported $0.30 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.30. Kiniksa Pharmaceuticals International had a net margin of 9.59% and a return on equity of 13.65%. The firm had revenue of $243.60 million for the quarter, compared to analyst estimates of $226.49 million. As a group, equities research analysts predict that Kiniksa Pharmaceuticals International will post 1.38 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Kiniksa Pharmaceuticals International news, Director G Bradley Cole sold 3,673 shares of the business’s stock in a transaction dated Wednesday, July 29th. The shares were sold at an average price of $81.43, for a total transaction of $299,092.39. Following the sale, the director directly owned 11,672 shares in the company, valued at $950,450.96. This represents a 23.94% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 51.98% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in KNSA. KBC Group NV acquired a new position in shares of Kiniksa Pharmaceuticals International in the first quarter valued at approximately $34,000. Smartleaf Asset Management LLC acquired a new stake in Kiniksa Pharmaceuticals International during the 4th quarter worth approximately $36,000. EverSource Wealth Advisors LLC lifted its holdings in Kiniksa Pharmaceuticals International by 140.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company’s stock worth $25,000 after buying an additional 532 shares in the last quarter. Nano Cap New Millennium Growth Fund L P purchased a new position in Kiniksa Pharmaceuticals International in the 4th quarter valued at approximately $41,000. Finally, CIBC Private Wealth Group LLC purchased a new position in Kiniksa Pharmaceuticals International in the 4th quarter valued at approximately $41,000. Hedge funds and other institutional investors own 53.95% of the company’s stock.

Key Headlines Impacting Kiniksa Pharmaceuticals International

Here are the key news stories impacting Kiniksa Pharmaceuticals International this week:

• Positive Sentiment: Kiniksa reported second-quarter revenue of $243.6 million, ahead of the $226.5 million consensus estimate, while adjusted earnings of $0.30 per share matched expectations. The results support continued commercial momentum and helped underpin the recent analyst optimism. Kiniksa Pharmaceuticals International 2026 Q2 Results Earnings Call Presentation
• Positive Sentiment: Several firms raised or reiterated bullish views. Goldman Sachs set a $90 price target, JPMorgan raised its target to $107, and Canaccord Genuity and Citigroup forecast additional appreciation. The broader analyst consensus remains “Buy,” with an average target of $87.38. Goldman Sachs Kiniksa Price Target JPMorgan Kiniksa Price Target
• Neutral Sentiment: Institutional ownership remains substantial at approximately 54%, with several funds increasing their positions. This may provide shareholder support, although the transactions cited largely reflect prior-quarter activity rather than a new catalyst.
• Negative Sentiment: Zacks Research downgraded KNSA from “Strong Buy” to “Hold.” The change may be contributing to profit-taking concerns after the stock’s sharp advance and elevated valuation.
• Negative Sentiment: Director G. Bradley Cole sold 3,673 shares at an average price of $81.43, reducing his position by 23.94%. While one insider sale does not establish a trend, it can weigh on sentiment, particularly near the stock’s recent high. G Bradley Cole Sells Kiniksa Shares

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.